New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus
Identifieur interne : 000306 ( PascalFrancis/Curation ); précédent : 000305; suivant : 000307New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus
Auteurs : John S. Oxford [Royaume-Uni] ; Shobana Balasingam [Royaume-Uni] ; Charlotte Chan [Royaume-Uni] ; Andrew Catchpole [Royaume-Uni] ; Robert Lambkin [Royaume-Uni]Source :
- Antiviral chemistry & chemotherapy [ 0956-3202 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Médicament, Vaccin, Santé publique.
English descriptors
- KwdEn :
Abstract
Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R0 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000684
Links to Exploration step
Pascal:05-0232555Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</title>
<author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S." last="Oxford">John S. Oxford</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0232555</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0232555 INIST</idno>
<idno type="RBID">Pascal:05-0232555</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000684</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000306</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</title>
<author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S." last="Oxford">John S. Oxford</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral chemistry & chemotherapy</title>
<title level="j" type="abbreviated">Antivir. chem. chemother.</title>
<idno type="ISSN">0956-3202</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral chemistry & chemotherapy</title>
<title level="j" type="abbreviated">Antivir. chem. chemother.</title>
<idno type="ISSN">0956-3202</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Drug</term>
<term>Immunoprophylaxis</term>
<term>Prevention</term>
<term>Public health</term>
<term>Review</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiviral</term>
<term>Médicament</term>
<term>Vaccin</term>
<term>Prévention</term>
<term>Immunoprophylaxie</term>
<term>Santé publique</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Relation structure activité</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Article synthèse</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term>
<term>Vaccin</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R<sub>0</sub>
value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0956-3202</s0>
</fA01>
<fA03 i2="1"><s0>Antivir. chem. chemother.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OXFORD (John S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BALASINGAM (Shobana)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHAN (Charlotte)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CATCHPOLE (Andrew)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LAMBKIN (Robert)</s1>
</fA11>
<fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>13-21</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22101</s2>
<s5>354000121167610020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>2 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0232555</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral chemistry & chemotherapy</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R<sub>0</sub>
value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>11</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>11</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>11</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Médicament</s0>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Drug</s0>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>12</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>14</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévention</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevention</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevención</s0>
<s5>15</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunoprophylaxie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunoprophylaxis</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunoprofilaxia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Public health</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>22</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Review</s0>
<s5>22</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>22</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>62</s5>
</fC07>
<fN21><s1>157</s1>
</fN21>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000306 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000306 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:05-0232555 |texte= New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus }}
This area was generated with Dilib version V0.6.33. |